Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
27.00
+0.31 (1.16%)
At close: Jun 26, 2026, 4:00 PM EDT
26.64
-0.36 (-1.33%)
After-hours: Jun 26, 2026, 5:37 PM EDT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Name | Position |
|---|---|
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder & Director Emeritus |
| Dr. Patrick E. Burnett M.D., Ph.D. | Executive VP & Chief Medical Officer |
| Mr. Brian Schoelkopf | Head of Investor Relations |
| Mr. Larry Todd Edwards | Executive VP & Chief Commercial Officer |
| Mr. Masaru Matsuda Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Mr. Steve Arias | Vice President of Compliance & Privacy |
| Mr. Todd Franklin Watanabe M.A. | President, CEO & Director |
| Ms. Aleen Hosdaghian | Vice President of Marketing |
| Ms. Amanda Sheldon | Head of Corporate Communications |
| Ms. Latha Vairavan | Senior VP & Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-09 | 8-K | arqt-20260605.htm |
| 2026-05-06 | 8-K | arqt-20260506.htm |
| 2026-05-06 | 10-Q | arqt-20260331.htm |
| 2026-04-21 | S-8 | arcutiss-8xapril2026.htm |
| 2026-04-21 | DEFA14A | a2026proxydefinitiveadditi.htm |
| 2026-04-21 | DEF 14A | arqt-20260421.htm |
| 2026-02-25 | S-8 | arcutiss-8xfebruary2026.htm |
| 2026-02-25 | S-3ASR | arcutis-sx3asrfeb26.htm |
| 2026-02-25 | 8-K | arqt-20260225.htm |
| 2025-12-08 | 8-K | arqt-20251203.htm |